Use of N-Acetylcysteine (NAC) in the Treatment of Repetitive Behaviors (RB) and Self-Injurious Behaviors (SIB) in Cornelia de Lange Syndrome: A Randomized Double-Blind Placebo-Controlled Pilot Study

This research project is a randomized cross-over pilot trial which aims to test the efficacy of N-acetylcysteine (NAC) for the treatment of Repetitive Behaviors (RB) and self-injurious behavior (SIB) in patients with Cornelia de Lange Syndrome (CdLs).
NAC is a known anti-oxidative stress and neuroprotective agent, which has been shown to decrease the occurrence of SIB such as skin picking. NAC has also shown partial response in trials for compulsive behaviors in Obsessive Compulsive Disorder (OCD) and related disorders in autism.
Cornelia de Lange syndrome (CdLS) is a genetic disorder with autistic features, including RBs and SIB. In this randomized clinical trial, participants with CdLS will be blindly assigned one of two possible treatment arms: 1) placebo (8 weeks) and NAC (8 weeks); or 2) NAC (8 weeks) and placebo (8 weeks), with an intermediate 2-week washout period.

Start Date01 Mar 2025

Sponsor / Collaborator

The Johns Hopkins University

IRCT20230629058615N3 / SuspendedPhase 3

Evaluation of the effects of a four-drug regimen with N-acetylcysteine and comparing it with a four-drug regimen in eradicating Helicobacter pylori in patients with Helicobacter pylori infection

Start Date19 Feb 2025

Sponsor / Collaborator

Aja University of Medical Sciences

NCT04520139 / Not yet recruitingPhase 1/2IIT

Phase I Dose-Escalating and Phase II Dose-Expansion Study of N-Acetyl-Cysteine (NAC) Administration to Ovarian Cancer Patients Receiving Platinum-Based Therapy (PBT) for the Mitigation of Chemotherapy-Related Cognitive Impairment (CRCI)

This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will investigate whether NAC will mitigate chemotherapy-related cognitive impairment (CRCI).

Start Date01 Dec 2024

Sponsor / Collaborator

University of California, Irvine

[+1]

100 Clinical Results associated with Acetylcysteine

100 Translational Medicine associated with Acetylcysteine

100 Patents (Medical) associated with Acetylcysteine

23,405

Literatures (Medical) associated with Acetylcysteine

01 Apr 2025·BIOMATERIALS

3D printing incorporating gold nanozymes with mesenchymal stem cell-derived hepatic spheroids for acute liver failure treatment

Article

Author: Chen, Xiaodie ; Tao, Yu ; Xu, Yanteng ; Li, Mingqiang ; Yi, Ke ; Jin, Yuanyuan ; Zhang, Jiabin ; Xue, Tiantian ; Wang, Haixia ; Lao, Yeh-Hsing ; Li, Fenfang ; Chan, Hon Fai ; Shao, Dan

Acute liver failure (ALF) is a highly fatal disease, necessitating the advancement and optimization of alternative therapeutic strategies to benefit patients awaiting liver transplantation. In this study, we innovatively established the antioxidant nanozyme-hepatocyte-like cells (HLCs) microtissue sheets (HS/N-Au@composite) for ALF therapy. We first prepared a 3D-printed hyaluronic acid/gelatin/sodium alginate scaffold with N-acetylcysteine (NAC)-capped gold nanoclusters (NAC-Au NCs), forming the N-Au@hydrogel. For the encapsulation of HLC spheroids, we used a biocompatible hybrid hydrogel composed of decellularized extracellular matrix (dECM), thrombin, and fibrinogen, resulting in the HS@dECM hydrogel. Utilizing 3D printing technology, we integrated the N-Au@hydrogel with the HS@dECM hydrogel to create the HS/N-Au@composite for in situ transplantation to treat ALF. Our results demonstrated that NAC-Au NCs effectively mitigated reactive oxygen species (ROS)-induced liver necrosis in ALF. Additionally, the N-Au@hydrogel provided mechanical support, ensuring the proper landing and effective functioning of the transplanted HLC spheroids. The HS/N-Au@composite synergistically decreased serum transaminase levels, reduced the accumulation of pro-inflammatory cytokines, accelerated liver function recovery, and promoted liver regeneration in ALF treatment. This combination of HLC spheroids and NAC-Au NCs nanozymes via 3D-printed composite scaffolds represents a promising strategy for enhancing hepatocyte transplantation and advancing stem cell regenerative medicine in ALF therapy.

01 Mar 2025·TOXICOLOGY IN VITRO

Polyamine-modified naphthalimide derivative 9C inhibits colorectal cancer through ROS-mediated ER stress, migration and invasion

Article

Author: Gao, Lei ; Xu, Xiaojuan ; Dai, Fujun ; Wang, Senzhen ; Wang, Yuxia ; Ge, Chaochao ; Xie, Songqiang ; Wang, Chaojie

Mounting evidence over the past decades has demonstrated the therapeutic potential of targeting endoplasmic reticulum (ER) stress signaling in cancer. Naphthalimdes exert their anti-cancer activities in a variety of ways. However, the effects of naphthalimides on ER stress are rarely reported. In this study, based on RNA-sequencing analysis, we observed that 9C, a naphthalimide derivative, could trigger ER stress to activate death receptor signaling and autophagy. Pretreatment of ER stress inhibitor, such as salubrinal, and autophagy inhibitor, such as 3-methyladenine (3-MA), partially reversed 9C-induced inhibition of cell growth. Furthermore, our results unveiled a reactive oxygen species (ROS)-dependent inhibitory effect of 9C. In addition, 9C inhibited colorectal cancer (CRC) cells migration and invasion. Removal of ROS using N-acetyl-L-cysteine (NAC) attenuated the expression of ATF4, CHOP, death receptors, E-cadherin, and the apoptosis and autophagy related proteins. Taken together, our results suggested that ROS-mediated ER stress, migration, and invasion is responsible for the therapeutic potential of naphthalimides including 9C in CRC.

01 Mar 2025·PLANT SCIENCE

Cytoprotective role of pyruvate in mitigating abiotic stress response in Arabidopsis thaliana

Article

Author: Mustafiz, Ananda ; Pelzang, Sangay ; Jain, Arushi ; Alam, Nazmir Binta

Pyruvate is a central metabolite in cellular respiration and metabolism. It can neutralize reactive oxygen species (ROS), safeguard mitochondrial membrane potential, and regulate gene expression under oxidative stress. However, its role in abiotic stress tolerance in plants needs to be explored. Therefore, the current study investigated the role of pyruvate and its metabolism in response to different abiotic stresses in the model plant Arabidopsis thaliana. We retrieved transcript profiling data for pyruvate metabolism and transportation genes (D-LDH, AlaAT, PK, MPC, PDC, PDH, NAD-ME) from public databases. The study's findings indicate that these genes' expression is regulated in response to different abiotic stresses. Moreover, the promoter region of these genes contained multiple cis-acting elements like ABRE, ARE, P-box, and MBS, which are associated with plants' abiotic stress response. Furthermore, colorimetric analysis showed higher pyruvate content under different abiotic stresses. Therefore, exogenous pyruvate treatment was given before and after different abiotic stresses, which could combat the toxicity of pro-oxidant molecules by pyruvate intake. The semiquantitative RT-PCR analysis revealed that exogenous pyruvate treatment enhances the expression of important transcription factors WRKY2, GH3.3, DREB2A, and bZIP1, and stress-responsive genes e.g., APX1, ERD5, ADC2, and HSP70 in addition to abiotic stresses. Moreover, Arabidopsis plants pre-treated with pyruvate before oxidative stress showed less RBOHD expression. Additionally, pyruvate's cytoprotective role was compared to other well-known antioxidants such as NAC, Trolox, and GSH. Finally, untargeted GC-MS/MS analysis of abiotic stress-treated Arabidopsis plants showed a higher metabolite level of β-hydroxy-pyruvic acid, indicating the crucial role of pyruvate during abiotic stress.

News (Medical) associated with Acetylcysteine

04 Dec 2024

·medcitynews.com

A Biotech Startup's Quest to Relieve Pulmonary Mucus Obstruction for Respiratory Care - MedCity News

MucoLife Therapeutics , an alumnus of the Health Wildcatters accelerator, develops patented, innovative mucus-dissolving therapies specifically targeting pulmonary mucus obstruction. In response to emailed questions, the founders shared their company’s approach, which is designed to help people with obstructive respiratory conditions, such as COPD, cystic fibrosis, asthma, and pulmonary fibrosis. Why did you start this company? MucoLife Therapeutics was born in 2024 from the visionary efforts of Thaher Pelaseyed and Gunnar Hansson, two trailblazing scientists from the Mucin Biology Groups (MBG) at the University of Gothenburg, Sweden. Renowned as a global leader in mucus-related disease research, MBG provided the fertile ground for this duo’s entrepreneurial spirit to flourish. Together, Pelaseyed and Hansson set out to translate decades of groundbreaking science into innovative solutions for debilitating mucus-driven diseases. Thaher Pelaseyed What need are you seeking to address in healthcare? With a combined six decades of expertise, Pelaseyed and Hansson identified a dire and often-overlooked challenge in healthcare: pulmonary mucus obstruction. Diseases such as chronic obstructive pulmonary disease COPD, cystic fibrosis, asthma, and pulmonary fibrosis often lead to thick, sticky mucus that clogs patients’ airways, fueling infections, inflammation, and permanent lung damage. Existing treatments largely fail to address this issue, and the current standard therapy, N-acetylcysteine (NAC), suffers from poor efficacy and significant side effects. MucoLife Therapeutics was founded to fill this void, offering modern, transformative therapies to improve the lives of patients suffering from chronic respiratory diseases. What does your product do? How does it work? Gunnar Hansson MucoLife Therapeutics is at the forefront of innovation with MLT-001, a patented first-in-class therapy poised to revolutionize the management of pulmonary mucus obstruction. Built on over 20 years of cutting-edge research, MLT-001 employs a patented mechanism that disrupts mucin protein interactions responsible for forming dense mucus plugs. Delivered as an inhalable therapy, MLT-001 efficiently dissolves these plugs, enabling effective mucus clearance—a feat that was not possible with earlier conventional treatments like NAC. This breakthrough offers renewed hope to patients struggling with obstructive respiratory conditions. Is this your first healthcare startup? What’s your background in healthcare? Yes, MucoLife is the first healthcare venture for both founders. Pelaseyed, a pharmacist with a PhD in medical biochemistry, honed his expertise in cell biology through postdoctoral research at Cornell University. Gunnar Hansson, a pioneer in mucus biology, has over 40 years of research experience spanning institutions such as the Mayo Clinic, the NIH, and the University of Gothenburg, supported by prestigious grants from the Bill & Melinda Gates Foundation, NIH, and the European Research Council. Together, they bring a rich legacy of scientific discovery to their entrepreneurial journey. What is your company’s business model? MucoLife Therapeutics’ business strategy focuses on developing patented, innovative mucus-dissolving therapies specifically targeting pulmonary mucus obstruction. The company’s approach includes a pipeline of differentiated first-in-class products, advancing from preclinical success to regulatory approval, and clinical trials, ultimately achieving exits through strategic partnerships with leading pharmaceutical companies. Who is your customer? MucoLife’s primary customers are the more than 600 million people who grapple with chronic respiratory diseases such as COPD, cystic fibrosis, asthma, and pulmonary fibrosis—conditions that currently lack effective treatments for mucus obstruction. How do you generate revenue? Revenue will be generated through licensing agreements and strategic partnerships, allowing pharmaceutical partners to bring MucoLife’s innovative therapies to market while funding further product development and expansion. Do you have clinical validation for your product? MucoLife’s patented lead candidate, MLT-001, has demonstrated remarkable preclinical success. Studies in a mouse model of COPD revealed that MLT-001 is 90% effective in dissolving mucus plugs and clearing the airways. Importantly, the therapy acts locally in lungs, minimizing systemic side effects. Its protein-based design ensures safety in the gastrointestinal tract, as it degrades harmlessly in the stomach and intestine if swallowed after inhalation. These findings set the stage for clinical validation, underscoring MLT-001’s potential as a game-changer in respiratory care. At what stage of development is your lead product? With preclinical studies completed, MucoLife Therapeutics is preparing to advance MLT-001 into Phase I clinical trials by late 2026. This milestone marks a significant step in the company’s mission to redefine treatment for pulmonary mucus obstruction.

Phase 1

06 Nov 2024

·www.prnewswire.com

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

NASHVILLE, Tenn., Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Cumberland is completing the FIGHT DMD™ trial, a multicenter, double-blind, placebo-controlled Phase II study investigating the pharmacokinetics, safety and efficacy of once daily oral Ifetroban in patients with DMD. Results will be announced later this year. "For Duchenne muscular dystrophy, a devastating genetic disorder affecting young boys, securing both Orphan Drug and Rare Pediatric Disease Designations for Ifetroban from the FDA is a critical step forward," said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals. "These designations not only recognize the urgent need for effective treatments but also provide vital support to accelerate research and development. These important regulatory milestones represent hope for families and a pathway to bring transformative medicines to a vulnerable patient population more quickly and efficiently." The U.S. FDA grants Rare Pediatric Disease Designation to incentivize drug development for life-threatening diseases affecting less than 200,000 children in the U.S. As these diseases pose unique challenges to drug development, special focus is needed to provide therapeutic options to these children. Companies that receive approval for a drug or biologic with this designation may be eligible for a voucher which may be redeemed for priority review of a different product. Additionally, this voucher may be transferred or sold to another sponsor. Orphan Drug Designation is granted by the U.S. FDA to encourage development of new therapies for rare diseases or conditions affecting fewer than 200,000 people in the U.S. This designation offers sponsors multiple incentives, which include exemption from user fees, tax credits for qualified clinical trials and potential market exclusivity for seven years following approval of the product. About Duchenne Muscular Dystrophy DMD is a rare and fatal genetic disorder which affects about 1 in every 3,300 male births worldwide. Characterized by mutations in the gene responsible for producing dystrophin, DMD causes damage to the skeletal and cardiac muscle of DMD patients, with cardiomyopathy recognized as the primary cause of death. Ifetroban is being evaluated to treat the heart disease associated with DMD, which has received limited attention with current therapies. About Ifetroban Ifetroban is a potent and selective thromboxane-prostanoid receptor (TPr) antagonist. Ifetroban exhibits high affinity for TPr on many cell types including cardiomyocytes, platelets, vascular and airway smooth muscle, and fibroblasts, and lacks agonistic activity. In several preclinical models of muscular dystrophy, including limb-girdle and Duchenne, ifetroban prevented cardiac fibrosis and cardiac dysfunction and improved mortality. Cumberland previously announced the acquisition of the ifetroban program in collaboration with Vanderbilt University and Cumberland Emerging Technologies. Cumberland is also evaluating ifetroban for systemic sclerosis and pulmonary fibrosis. The ongoing FIGHTING FIBROSIS Trial is a multicenter, randomized placebo-controlled Phase II study in patients with idiopathic pulmonary fibrosis (IPF), a progressive interstitial lung disease. IPF is marked by inflammation and fibrosis of the lungs, resulting in rapidly declining lung function and reduced survival within five years of diagnosis. The study is evaluating the safety and efficacy of once daily oral Ifetroban for 52 weeks. About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. The Company develops, acquires, and commercializes brands for the hospital acute care, gastroenterology and rheumatology market segments. The Company's portfolio of FDA-approved brands includes: Acetadote® (acetylcysteine) Injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) Injection, for the treatment of pain and fever; Vaprisol® (conivaptan) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ® (telavancin) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; Kristalose® (lactulose) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation; and Sancuso® (granisetron) Transdermal delivery system, for the treatment of nausea and vomiting associated with chemotherapy. For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the Company's website . About Cumberland Emerging Technologies Cumberland Emerging Technologies, Inc. () is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, Launch Tennessee and WinHealth Pharma. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace. CET helps manage the development and commercialization process for select projects and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure to early-stage life sciences companies. Forward-Looking Statements This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company's most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. SOURCE Cumberland Pharmaceuticals Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Orphan DrugAcquisitionClinical Result

05 Nov 2024

·www.prnewswire.com

New Study Compares Caldolor® (ibuprofen injection) to ketorolac

– Real World Study Compared Over 150,000 Adult & Pediatric Patients – – Caldolor Associated with Fewer Adverse Drug Reactions – – Caldolor also Improved Healthcare Utilization – NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (Nasdaq: CPIX) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations. The study, published in Frontiers of Pain Research, provides compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions (ADRs) and improved healthcare utilizations when compared to ketorolac. This extensive, retrospective, payer database analysis evaluated the records of over 17 million patients who had received either ketorolac or Caldolor. Ultimately, 31,046 Caldolor and 124,184 ketorolac adult patients were selected and compared for ADRs and subsequent healthcare resource utilization, which includes inpatient, outpatient and emergency department visits as well as all procedures and prescriptions during the follow up time of 29 days. An additional 5,579 pediatric patients were identified in each arm and compared in a separate claims analysis. Key findings reveal that, in adults, Caldolor was associated with a 45% reduction in renal dysfunction (p<0.001) and a 78% decrease in hematuria rates (p<0.001) when compared to ketorolac. Notably, patients also experienced fewer gastrointestinal complications as well as reduced headaches, nausea and abdominal pain. Among pediatric patients, the results showed Caldolor was associated with a 51-65% lower rate of ADRs, including headache and nausea, with 95% confidence intervals supporting clinical significance. Caldolor also demonstrated a positive impact on healthcare resource utilization (HCRU) when compared to ketorolac, with decreased emergency room and outpatient visits, as well as a shortened hospital length of stay for both adults and children. "These findings underscore Caldolor's potential to improve patient care by reducing their treatment complications, while also delivering potential savings for healthcare systems through decreased hospital readmissions and shortened treatment times," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. About Caldolor® (ibuprofen) Injection Caldolor is indicated in adults and pediatric patients for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with a history of asthma or other allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. For full prescribing and safety information, including boxed warning, visit . About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation; Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy, Systemic Sclerosis and Idiopathic Pulmonary Fibrosis. For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company's website . Forward-Looking Statements This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company's most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. SOURCE Cumberland Pharmaceuticals Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultDrug ApprovalPhase 2

100 Deals associated with Acetylcysteine

External Link

KEGG	Wiki	ATC	Drug Bank
D00221	Acetylcysteine	V03AB23 S01XA08 R05CB01	DB06151

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nails, Ingrown	JP	Maruho Co., Ltd.	27 Mar 2023
Acetaminophen overdose	AU	Pfizer Australia Pty Ltd.	17 Jul 2006
Pulmonary Disease, Chronic Obstructive	CN	Jiangsu Jibeier Pharmaceutical Co. Ltd.	01 Jan 1985
Asthma	JP	Sannova KK	05 Jan 1965
Bronchiectasis	JP	Sannova KK	05 Jan 1965
Bronchitis, Chronic	JP	Sannova KK	05 Jan 1965
Cystic Fibrosis	JP	Sannova KK	05 Jan 1965
Laryngitis	JP	Sannova KK	05 Jan 1965
Pharyngitis	JP	Sannova KK	05 Jan 1965
Pneumonia	JP	Sannova KK	05 Jan 1965
Pulmonary Emphysema	JP	Sannova KK	05 Jan 1965
Pulmonary Tuberculosis	JP	Sannova KK	05 Jan 1965
Chemical and Drug Induced Liver Injury	US	Apothecon LLC	14 Sep 1963
Liver Injury	US	Apothecon LLC	14 Sep 1963

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bronchitis	NDA/BLA	CN	Zambon Switzerland Ltd.	21 Feb 2022
Acute Bronchitis	Phase 3	CN	Zambon SpA	21 Jun 2019
Acute Bronchitis	Phase 3	CN	Zambon Switzerland Ltd.	21 Jun 2019
Idiopathic Pulmonary Fibrosis	Phase 3	BE	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	FR	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	DE	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	IT	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	NL	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	ES	Zambon SpA	01 Mar 2000
Idiopathic Pulmonary Fibrosis	Phase 3	GB	Zambon SpA	01 Mar 2000

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00558142 (CTgov)	Phase 4	Kidney Diseases	107	placebo+Acetylcysteine (Healthy Volunteers, no Contrast)	qrfuvimjel(hdvexlkagj) = rlotzoboak khphrefkqu (yjqkuxrkpj, orssossrwr - pxjuvhunra) View more	-	19 Sep 2024
				placebo+Acetylcysteine (Volunteers With CKD III, no Contrast)	qrfuvimjel(hdvexlkagj) = jlwmrxdbub khphrefkqu (yjqkuxrkpj, bloebwmerj - fnhkfjaaad) View more
NCT03253328 (CTgov)	Early Phase 1	Chronic Limb-Threatening Ischemia \| Diabetes Mellitus \| Leg Injuries	33	Active Arm N-acetyl cysteine (NAC) (Active Arm N-acetyl Cysteine (NAC))	fduuujpbpq(eznmtmsyvf) = ynaslxwktl kcsitmypbs (qvitlbxgrw, wxfxjsctds - pbnxfslpxh) View more	-	16 Aug 2024
				Placebo Arm (Placebo Arm)	fduuujpbpq(eznmtmsyvf) = breqymwarf kcsitmypbs (qvitlbxgrw, iuamcfzqpf - iajppfjezh) View more
AUA2024	Not Applicable	Non-Muscle Invasive Bladder Neoplasms	-	NAC (Patients with variant histology (VH))	xlnmngegdz(zrahtrbbts) = ajwanmepbx yeuimkspzf (gbqyyikunk )	-	01 May 2024
				NAC (Patients with carcinoma in situ (CIS))	xlnmngegdz(zrahtrbbts) = geikcgksvs yeuimkspzf (gbqyyikunk )
NCT03499249 (CTgov)	Phase 2	Biliary Atresia	13	N-Acetyl Cysteine	ecjyikiqms(vkuaflztcu) = jacvhloayl qwnejfhimr (plkosfzuti, tbotaapuiy - knruicerhn) View more	-	10 Jan 2024
AASLD2023	Not Applicable	Hepatitis, Alcoholic	30	N-acetylcysteine	ftgnzjuvtz(clpgisjunj) = vzkfunnoac ejtoxbdvum (llftjfjoes )	-	10 Nov 2023
AASLD2023	Not Applicable	Hepatitis A amphetamine use	95	Amphetamine users	lzdvutmcud(tycxpfwjzf) = mrlerbdsev sbwunwutki (rxwuffzgle ) View more	-	10 Nov 2023
				Non-users	lzdvutmcud(tycxpfwjzf) = ruylogatqc sbwunwutki (rxwuffzgle ) View more
NCT04562597 (Pubmed \| Pain Manag)	Phase 1/2	-	50	N-acetylcysteine (NAC) 0 mg/kg	nekursfsgz(mfnuqemyfc) = bsvhdsgvsv ikezzrcenn (llwpfqctdv )	Positive	01 Oct 2023
				N-acetylcysteine (NAC) 50 mg/kg	nekursfsgz(mfnuqemyfc) = gumqbsmefg ikezzrcenn (llwpfqctdv )
NCT04005053 (CTgov)	Phase 2	Depressive Disorder \| Suicidal Ideation \| Self-Injurious Behavior	44	N-Acetyl Cysteine (Low-Dose NAC)	laceooguwi(kdgeimqgxv) = fxemrpdpff wuocfyxvho (zedlcefuky, faanhkapwl - kukkubuebn) View more	-	15 Aug 2023
				N-Acetyl Cysteine (High-Dose NAC)	laceooguwi(kdgeimqgxv) = qaehvoohjp wuocfyxvho (zedlcefuky, bqouoxcppu - wzbdzgvzbt) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis